Beard C et al. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer. Urology 2005;66(5):1020-3. Abstract

D’Amico AV et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294(4):440-7. Abstract

Dotan ZA et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23(9):1962-8. Abstract

Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract

Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 2005;23(32):8204-11. Abstract

Lee AK, D’Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23(32):8192-7. Abstract

Lee AK et al. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005;63(2):456-62. Abstract

Lin DD et al. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 2005;65(3):528-32. Abstract

Sengupta S et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174(6):2191-6. Abstract

Stewart AJ et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005;23(27):6556-60. Abstract

Zhou P et al. Predictors of prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23(28):6992- 8. Abstract